Novartis to buy Takeda eye drug assets in US$3.4bil deal


HONG KONG: Novartis AG has agreed to pay US$3.4bil for eye-disease medicines that Takeda Pharmaceutical Co is selling to shed debt after its US$62bil acquisition of Shire Plc.

The main product in the deal is Xiidra, prescription drops that compete with Allergan Plc’s blockbuster Restasis to relieve dry-eye disease, a common condition that can hinder daily activities ranging from reading to driving. Along with US$3.4bil in cash upfront, Novartis agreed to pay as much as US$1.9bil in milestones.

Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
   

Next In Business News

Domestic investors show growing confidence in Malaysia - Tengku Zafrul
MSM Malaysia extends CFO's garden leave until Jan 15
Mah Sing to develop M Azura in Setapak with GDV of RM508mil
Ringgit to strengthen vs USD this month, foreign investors made November comeback: Kenanga Research
FBM KLCI little changed at midday
Coffee trader Mercon runs out of credit, files for bankruptcy
Japan's Q3 GDP falls faster than first estimates as consumption sags
Maybank appoints Alvin Lee as CEO for Singapore effective Jan 1
Ringgit opens firmer vs US dollar
CDC bags four awards at Malaysia Public Relations Awards 2023

Others Also Read